MTOR and prostate carcinoma: Interestingly, in 2010 Dubrovska and colleagues showed how a combinatorial approach, based on conventional chemotherapy and NVP-BEZ235, a dual PI3K/mTOR inhibitor, leads to significant tumor regression targeting both bulk tumor cells and prostate cancer progenitors (PCPs), respectively.